These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 12796026)

  • 1. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Pfreundschuh M; Zwick C; Zeynalova S; Dührsen U; Pflüger KH; Vrieling T; Mesters R; Mergenthaler HG; Einsele H; Bentz M; Lengfelder E; Trümper L; Rübe C; Schmitz N; Loeffler M;
    Ann Oncol; 2008 Mar; 19(3):545-52. PubMed ID: 18065407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
    Pfreundschuh M; Trümper L; Kloess M; Schmits R; Feller AC; Rudolph C; Reiser M; Hossfeld DK; Metzner B; Hasenclever D; Schmitz N; Glass B; Rübe C; Loeffler M;
    Blood; 2004 Aug; 104(3):626-33. PubMed ID: 14982884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
    Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
    Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
    Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
    Pfreundschuh M; Trümper L; Kloess M; Schmits R; Feller AC; Rübe C; Rudolph C; Reiser M; Hossfeld DK; Eimermacher H; Hasenclever D; Schmitz N; Loeffler M;
    Blood; 2004 Aug; 104(3):634-41. PubMed ID: 15016643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
    Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
    Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
    Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
    Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
    Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
    Trümper L; Zwick C; Ziepert M; Hohloch K; Schmits R; Mohren M; Liersch R; Bentz M; Graeven U; Wruck U; Hoffmann M; Metzner B; Hasenclever D; Loeffler M; Pfreundschuh M;
    Ann Oncol; 2008 Mar; 19(3):538-44. PubMed ID: 18212092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
    Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
    J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma.
    Itoh K; Ohtsu T; Wakita H; Igarashi T; Ishizawa K; Onozawa Y; Fujii H; Minami H; Sasaki Y
    Ann Oncol; 2000 Oct; 11(10):1241-7. PubMed ID: 11106111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
    Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
    Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group.
    Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M
    Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.